Showing 3371-3380 of 10546 results for "".
Therapeutics Update
https://practicaldermatology.com/topics/psoriasis/therapeutics-update/20530/New products and pharmacologic developmentsVisitation Rights
https://practicaldermatology.com/topics/practice-management/visitation-rights/20535/Tips for getting the most out of an onsite visit to a colleague's practice.Currents: Win the Adherence Game: Don't Leave Patient Outcomes to Chance
https://practicaldermatology.com/topics/practice-management/win-the-adherence-game/20538/Don't leave patient outcomes to chancePractical Dermatology® Magazine Recognizes Top Content
https://practicaldermatology.com/topics/practice-management/practical-dermatology-magazine-recognizes-top-content/20563/Here's the most popular content from Practical Dermatology® brands online.Currents
https://practicaldermatology.com/topics/practice-management/currents/20575/Aesthetic developments herald the dawn of a new age of rejuvenation.New Products; Therapeutics Focus: Fungal Infections
https://practicaldermatology.com/columns/new-products/new-products-therapeutics-focus-fungal-infections/20631/New Products
https://practicaldermatology.com/columns/new-products/new-products/20650/New products and pharmacologic developmentsTerrence Keaney, MD, FAAD
https://practicaldermatology.com/topics/practice-management/terrence-keaney-md-faad/20644/Making the leap to private practice in 2017The Importance of Employee Engagement
https://practicaldermatology.com/topics/general-topics/the-importance-of-employee-engagement/20639/The most valuable asset to your medical practice is not what you think.Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkuma